PMID- 34747904
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 33
IP  - 11
DP  - 2021 Nov 10
TI  - The use of pharmacogenetic testing in psychiatry.
PG  - 849-851
LID - 10.1097/JXX.0000000000000666 [doi]
AB  - Psychiatric pharmacogenetic testing is commonly used by providers in primary care 
      and mental health settings. The purpose of this article is to describe the extent 
      to which psychiatric pharmacogenetic testing supports clinical practice. human 
      leukocyte antigen (HLA)-A and HLA-B should be tested before initiating 
      carbamazepine and oxcarbazepine due to risk of serious skin reactions. For 
      psychotropic medications metabolized through the liver, limited evidence suggests 
      testing for variation in metabolism through CYP2D6 and CYP2D19. For specific 
      medication and genotype-phenotype variations, guidance through the Clinical 
      Pharmacogenetics Implementation Consortium (CPIC) or the International Society of 
      Psychiatric Genetics (ISPG) should be reviewed. Commercial tests interpret this 
      information differently and should not be used for broad guidance. Clinicians 
      should follow current guidelines from professional bodies such as CPIC or ISPG 
      and test for HLA-A or HLA-B before initiating carbamazepine or oxcarbazepine. 
      Evidence is limited for psychiatric pharmacogenetic testing. Clinicians should 
      continue to follow best practice and clinical practice guidelines.
CI  - Copyright (c) 2021 American Association of Nurse Practitioners.
FAU - Kumar, Aparna
AU  - Kumar A
AD  - Department of Psychiatry and Human Behavior, Jefferson Hospital.
AD  - Jefferson University, Philadelphia, PA.
FAU - Kearney, Anne
AU  - Kearney A
AD  - Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's 
      Hospital of Philadelphia (CHOP), Philadelphia, PA.
LA  - eng
PT  - Journal Article
DEP - 20211110
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
MH  - Cytochrome P-450 CYP2D6/genetics
MH  - Humans
MH  - Pharmacogenetics
MH  - *Pharmacogenomic Testing
MH  - *Psychiatry
COIS- Competing interests: The authors report no conflicts of interest.
EDAT- 2021/11/09 06:00
MHDA- 2021/11/25 06:00
CRDT- 2021/11/08 12:19
PHST- 2021/04/12 00:00 [received]
PHST- 2021/09/16 00:00 [accepted]
PHST- 2021/11/08 12:19 [entrez]
PHST- 2021/11/09 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 01741002-202111000-00002 [pii]
AID - 10.1097/JXX.0000000000000666 [doi]
PST - epublish
SO  - J Am Assoc Nurse Pract. 2021 Nov 10;33(11):849-851. doi: 
      10.1097/JXX.0000000000000666.